Witnessing the stock’s movement on the chart, on Thursday, Corcept Therapeutics Inc (NASDAQ: CORT) had a quiet start as it plunged -4.45% to $35.39, before settling in for the price of $37.04 at the close. Taking a more long-term approach, CORT posted a 52-week range of $32.99-$117.33.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 9.89%. Meanwhile, its Annual Earning per share during the time was 9.89%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -28.34%. This publicly-traded company’s shares outstanding now amounts to $105.12 million, simultaneously with a float of $92.90 million. The organization now has a market capitalization sitting at $3.72 billion.
Corcept Therapeutics Inc (CORT) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Corcept Therapeutics Inc’s current insider ownership accounts for 11.68%, in contrast to 74.02% institutional ownership. According to the most recent insider trade that took place on Jan 06 ’26, this organization’s Chief Development Officer sold 20,000 shares at the rate of 35.18, making the entire transaction reach 703,656 in total value, affecting insider ownership by 1,235.
Corcept Therapeutics Inc (CORT) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.05 per share during the current fiscal year.
Corcept Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -28.34% and is forecasted to reach 0.57 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 29.41% through the next 5 years, which can be compared against the 9.89% growth it accomplished over the previous five years trading on the market.
Corcept Therapeutics Inc (NASDAQ: CORT) Trading Performance Indicators
Let’s observe the current performance indicators for Corcept Therapeutics Inc (CORT). It’s Quick Ratio in the last reported quarter now stands at 3.07. Alongside those numbers, its PE Ratio stands at $40.44, and its Beta score is 0.24. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.02. Similarly, its price to free cash flow for trailing twelve months is now 22.90.
In the same vein, CORT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.88, a figure that is expected to reach 0.25 in the next quarter, and analysts are predicting that it will be 0.57 at the market close of one year from today.
